Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) Completed Phase 3 Trials for Flu caused by Influenza Prevention

CompletedPrevention3 IdentifierTitleDrugs
NCT01711736Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age
NCT00764790Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
NCT00319098Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
NCT00529516Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
NCT00100399Fluarix Immunogenicity and Safety Trial
NCT00345904Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above
NCT00380211Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults